SynAct Pharma has received IND approval from the FDA, meaning that they can initiate the phase IIa/b RESOLVE study of AP1189 in DMARD-IR patients. They have also just published their report for the third quarter, a busy period with significant progress in the development programmes with AP1189. CSO Thomas Jonassen visited BioStock’s studio to talk about the IND approval, patient recruitment in the EXPAND study, financing, and partnering discussions.
Watch the interview with Thomas Jonassen, CSO SynAct Pharma, below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.